The Netherlands
Aidence, founded in 2015 and headquartered in The Netherlands, is a promising player at the intersection of AI, Health Care, and Information Technology. Specializing in AI-powered clinical applications, Aidence is dedicated to enhancing the lung cancer care pathway. Their mission-driven approach focuses on transforming complex data into solutions that streamline the work of physicians and improve patient outcomes.
Their flagship product, Veye Lung Nodules, is a CE certified tool designed for managing pulmonary nodules. It is actively used in clinical settings and lung cancer screenings across Europe, delivering faster diagnostics, reduced misdiagnosis, and early detection of lung cancer.
A significant development in Aidence’s journey was its acquisition by RadNet on 01 January 2022, marking their last investment activity. As they continue to innovate within RadNet’s AI division, Aidence presents an enticing opportunity for investors seeking to tap into the rapidly evolving healthcare technology landscape with a proven and impactful solution.
